Article Details

BioNTech's Bispecific Elicits Treatment Response in Majority of SCLC Patients - BioSpace

Retrieved on: 2025-03-28 13:13:34

Tags for this article:

Click the tags to see associated articles and topics

BioNTech's Bispecific Elicits Treatment Response in Majority of SCLC Patients - BioSpace. View article details on hiswai:

Excerpt

More than 85% of patients with small-cell lung cancer dosed with BioNTech's investigational bispecific antibody BNT327 responded to the treatment, ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo